The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Dr. Manson covers the importance of treating the underlying driver of HLH to prevent recurrence and improve patient outcomes. She also highlights resources like the “Getting It Right First Time” (GURFT) guidelines and the Hi-HASK collaboration.
Prof. Amanda Goodall, director of the Executive Master’s in Medical Leadership (EMML), a specialized MSc degree from Bayes Business School offering advanced leadership training to medical doctors, joined SOHO Insider podcast host Prof. Christopher Fox, a professor of hematology at Nottingham University Hospitals NHS Trust, for a discussion on leadership in healthcare.
The approval is based on the phase 3 BRUIN CLL-321 trial, the first randomized study in patients pre-treated with a covalent BTK inhibitor. Pirtobrutinib monotherapy significantly prolonged progression-free survival versus investigator’s choice (idelalisib + rituximab or bendamustine + rituximab), with lower discontinuation due to treatment-related adverse events
Iberdomide is the first in a new class of medicines called cereblon E3 ligase modulator (CELMoD) agents, which utilize targeted protein degradation to reach proteins previously considered undruggable.
The filing was supported by results from the phase 2 PROSPECT study, which demonstrated an overall response rate of 67 percent and a complete response rate of 44 percent. A global phase 3 trial is currently recruiting patients to serve as a confirmatory study for the indication.
To access the SOHO Career Center click the following link.
